All News
RheumNow Podcast - I Wanna New Drug (8-30-19)
Dr. Jack Cush vents on choosing new therapies in rheumatoid arthritis.
Read Article
High-Dose Vitamin D: No Help for Bone Health
Vitamin D might not be much help for strengthening bones among healthy adults without osteoporosis, Canadian researchers reported, even at doses far higher than recommended daily allowances.
In a clinical trial assessing three levels of daily vitamin D supplementation -- 400 IU, 4,000 IU, and 10,000 IU -- radial volumetric bone mineral density was significantly lower among those (ages 55-70) taking higher doses for 3 years, according to Steven Boyd, PhD, of the University of Calgary in Canada, and colleagues.
Checkpoint Inhibitors: Who Gets Myocarditis?
The usual risk factors for myocarditis may not apply to who gets it while on immune checkpoint inhibiting cancer drugs, an FDA adverse event database suggested.
Read ArticleTaltz FDA Approved for Ankylosing Spondylitis (Radiographic Axial SpA)
The FDA has approved the IL-17A inhibitor Taltz (ixekizumab) for the treatment of adults with active ankylosing spondylitis (AS: also known as radiographic axial spondyloarthritis).
Read ArticleACR/SPARTAN Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
The American College of Rheumatology (ACR), in partnership with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network (SPARTAN), released the 2019 Update of the Recommendations for the Treatment of Ankylosing Spondylitis (AS) and Nonradiographic Axi
Read ArticleRheumNow Podcast – Upadacitinib FDA Approved for RA (8.23.19)
Dr. Jack Cush reports on the news and journal reports from the past week on RheumNow.com, including: how your genetics may shape your microbiome; GERD as a risk factor for TMJ?; how can MDA-5+ dermatomyositis be any worse; new drug happenings; StillsNow.com; and more.
Read ArticleA Multidimensional Definition of Remission
A study from Leeds suggests 'multi-dimensional remission' (MDR) can be seen in one-third of RA patients achieving DAS28-remission; such patients have better patient-reported outcome measures, making it an optimal goal, especially from a patient's perspective.
Read Article
FDA grants breakthrough status to OFEV (nintedanib) forthe treatment of chronic fibrosing interstitial lung diseases (ILDs), other than idiopathic pulmonary fibrosis (which it is currently approved for). Nintedanib has been studied in PSS ILD. https://t.co/K0ZTyqrfh6
Links:
Dr. John Cush RheumNow ( View Tweet)

Dr. John Cush RheumNow ( View Tweet)

Dr. John Cush RheumNow ( View Tweet)

Dr. John Cush RheumNow ( View Tweet)

ATAP ATAPAdvocates ( View Tweet)

Dr. John Cush RheumNow ( View Tweet)

Links:
Dr. John Cush RheumNow ( View Tweet)

Dr. John Cush RheumNow ( View Tweet)

Dr. John Cush RheumNow ( View Tweet)

RCT of 139 knee OA pts given either curcumin 500-mg tid or diclofenac 50-mg bid. At days 14 and 28 both had similar improvement in pain and KOOS score; but curcumin had better tolerance, less GI sxs and H2 blocker use. https://t.co/tcsDQWQOMg

Links:
Dr. John Cush RheumNow ( View Tweet)

Dr. John Cush RheumNow ( View Tweet)

Links:
Dr. John Cush RheumNow ( View Tweet)